Pathstone Holdings
PACB icon

Pathstone Holdings’s Pacific Biosciences PACB Stock Holding History

Pathstone Holdings’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,178
Closed -$30.3K – 2304
2025
Q4 		$30.3K Buy
16,178
+132
+0.8% +$254 ﹤0.01% 2204
2025
Q3 		$20.5K Buy
16,046
+4,158
+35% +$5.63K ﹤0.01% 2320
2025
Q2 		$14.7K Sell
11,888
-29,196
-71% -$33.7K ﹤0.01% 2178
2025
Q1 		$48.5K Buy
41,084
+20,542
+100% +$31.5K ﹤0.01% 2179
2024
Q4 		$37.6K Sell
20,542
-11,237
-35% -$21.9K ﹤0.01% 2273
2024
Q3 		$54K Buy
31,779
+21,560
+211% +$35.4K ﹤0.01% 2279
2024
Q2 		$14K Sell
10,219
-5,704
-36% -$11.5K ﹤0.01% 2295
2024
Q1 		$59.7K Buy
15,923
+729
+5% +$4.27K ﹤0.01% 2249
2023
Q4 		$149K Buy
+15,194
New +$124K ﹤0.01% 2104

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Pathstone Holdings's PACB Position: Q1 2026 in Review

Pathstone Holdings sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 16,178 shares — an estimated $30.3K sold.

Pathstone Holdings first reported a position in PACB in Q4 2023 and held it in 9 quarters. The position peaked at $149K in Q4 2023. 231 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Pathstone Holdings reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
  • Pathstone Holdings sold 16,178 Pacific Biosciences shares in Q1 2026, an estimated $30.3K.
  • Pathstone Holdings first reported a position in Pacific Biosciences in Q4 2023 and held it in 9 quarters.
  • Pathstone Holdings's Pacific Biosciences position peaked at $149K in Q4 2023.
  • 231 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.